FDA warned Synovo Production of Fullerton, CA over unapproved cementless hip implants and quality system failures.
What happened
FDA inspected Synovo Production, Inc. in Fullerton, CA from October 11 to October 26, 2022. Investigators found the Femoral Resurfacing Cup had been changed to a cementless coating without a new 510(k) clearance, and that the Total Hip System was being sold without the required premarket approval (PMA, the FDA's approval process for high-risk class III devices). The inspection also found many quality system failures, no FDA registration or device listing, and FDA said it had not received the firm's promised written response.
What FDA found
The firm changed the cup's coating to one for cementless fixation, a significant change from its 1991 clearance, but never filed a new 510(k) before selling it.
21 CFR 807.81(a)(3); section 502(o) of the ActThe Total Hip System is a class III device sold without an approved premarket approval (PMA) or an investigational device exemption.
Section 501(f)(1)(B) of the Act; 21 CFR 888.3410The firm switched from a sintered bead coating to a titanium plasma spray coating in April 2020 and dropped a second machining step, with no evidence either process change was validated.
21 CFR 820.75(a)At a surgeon's request the firm made three shortened-stem units of Lot 01030049T without documenting the design change or doing verification and validation.
21 CFR 820.30(a)A corrective action for poor coating adhesion was closed without evidence that it actually worked.
21 CFR 820.100(a)The firm used a re-packager/sterilizer and a raw material supplier before completing supplier assessments, and lacked records of management review, internal audits, and employee training.
21 CFR 820.50; 820.20(c); 820.22; 820.25(b)
What FDA wants
FDA told the firm to immediately stop making and shipping the modified Femoral Resurfacing Cup and Total Hip System labeled for non-cemented use, and to send a written plan within 15 business days describing corrections, corrective actions that fix the root causes, and a timetable for anything not yet finished.
Who should pay attention
- orthopedic surgeons and hospitals implanting hip devices
- distributors and purchasing groups sourcing hip implants
- packagers, sterilizers and raw material suppliers serving device makers
This is a summary. Read the original letter on fda.gov.